Literature DB >> 12805470

High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment.

Elizabeth R Johnston1, Lynn S Zijenah, Solomon Mutetwa, Rami Kantor, Chonticha Kittinunvorakoon, David A Katzenstein.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) subtype C viruses have been found to almost exclusively use the chemokine receptor CCR5 as a coreceptor for entry, even in patients with advanced AIDS. We have characterized subtype C virus isolates from 28 patients from Harare, Zimbabwe, 20 of whom were receiving antiretroviral treatment. Virus from 10 of the treated patients induced syncytium formation (SI virus) when cultured with MT2 cells. Only non-syncytium-inducing (NSI) virus was cultured from the peripheral blood mononuclear cells of the eight patients who had not received treatment. The majority of these subtype C SI viruses were capable of using both CCR5 and CXCR4 as coreceptors for viral entry, and the consensus V3 loop sequences from the SI viruses displayed a high net charge compared to those of NSI viruses. While those on treatment had reverse transcriptase (RT) and protease mutations, there was no clear association between RT and protease drug resistance mutations and coreceptor tropism. These results suggest that CXCR4-tropic viruses are present within the quasispecies of patients infected with subtype C virus and that antiretroviral treatment may create an environment for the emergence of CXCR4 tropism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805470      PMCID: PMC164829          DOI: 10.1128/jvi.77.13.7682-7688.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.

Authors:  G Pollakis; S Kang; A Kliphuis; M I Chalaby; J Goudsmit; W A Paxton
Journal:  J Biol Chem       Date:  2001-01-16       Impact factor: 5.157

2.  Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.

Authors:  A Singh; R G Collman
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.

Authors:  J K Nicholson; S W Browning; R L Hengel; E Lew; L E Gallagher; D Rimland; J S McDougal
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

5.  Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy.

Authors:  N Holtkamp; A Otteken; S Findhammer; V Miller; R Kurth; A Werner
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy.

Authors:  S Philpott; B Weiser; K Anastos; C M Kitchen; E Robison; W A Meyer; H S Sacks; U Mathur-Wagh; C Brunner; H Burger
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

7.  Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.

Authors:  Ronald P van Rij; Janny A Visser; Rieneke M E van Praag; Ronald Rientsma; Jan M Prins; Joep M A Lange; Hanneke Schuitemaker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India.

Authors:  D Cecilia; S S Kulkarni; S P Tripathy; R R Gangakhedkar; R S Paranjape; D A Gadkari
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

9.  N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection.

Authors:  Y Li; M A Rey-Cuille; S L Hu
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-01       Impact factor: 2.205

10.  Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000.

Authors:  Saladin Osmanov; Claire Pattou; Neff Walker; Bernhard Schwardländer; Jose Esparza
Journal:  J Acquir Immune Defic Syndr       Date:  2002-02-01       Impact factor: 3.731

View more
  35 in total

1.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.

Authors:  Georgios Pollakis; Almaz Abebe; Aletta Kliphuis; Moustapha I M Chalaby; Margreet Bakker; Yohannes Mengistu; Margreet Brouwer; Jaap Goudsmit; Hanneke Schuitemaker; William A Paxton
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

5.  Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa.

Authors:  Taryn N Green; Mohendran Archary; Michelle L Gordon; Nagavelli Padayachi; Yolanda Lie; Elizabeth D Anton; Jacqueline D Reeves; Anneke Grobler; Raziya Bobat; Hoosen Coovadia; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

6.  Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5).

Authors:  Elizabeth Johnston White; Bryan McColgan; Seble Kassaye; Lynn Zijenah; David Katzenstein
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

7.  Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Authors:  Seble Kassaye; Elizabeth Johnston; Bryan McColgan; Rami Kantor; Lynn Zijenah; David Katzenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

8.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells.

Authors:  Grant R Campbell; Stephen A Spector
Journal:  J Biol Chem       Date:  2008-09-10       Impact factor: 5.157

10.  HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Authors:  Maud Mavigner; Pierre Delobel; Michelle Cazabat; Martine Dubois; Fatima-Ezzahra L'faqihi-Olive; Stéphanie Raymond; Christophe Pasquier; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.